Unknown

Dataset Information

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.


ABSTRACT:

Background

Erythropoiesis-stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower "standard doses" (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking.

Methods

A cohort of 104 MDS patients treated with HD was retrospectively compared to 208 patients treated with SD in a propensity score-matched analysis to evaluate hematological improvement-erythroid (HI-E) rate induced by the different doses of rhEPO. The impact of rhEPO doses on survival and progression to leukemia was also investigated.

Results<

SUBMITTER: Balleari E 

PROVIDER: S-EPMC6912022 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature